Quinolone-Containing Therapies in the Eradication of Helicobacter pylori

Abstract EN

Fluoroquinolones, especially levofloxacin, are used in the eradication of Helicobacter pylori worldwide.

Many consensus guidelines recommend that the second-line rescue therapy for H.

pylori eradication consists of a proton pump inhibitor, a quinolone, and amoxicillin as an option.

Unfortunately, quinolone is well associated with a risk of developing bacterial resistance.

In this paper, we review quinolone-containing H.

pylori eradication regimens and the challenges that influence the efficacy of eradication.

It is generally suggested that the use of levofloxacin should be confined to “rescue” therapy only, in order to avoid a further rapid increase in the resistance of H.

pylori to quinolone.

The impact of quinolone-containing H.

pylori eradication regimens on public health issues such as tuberculosis treatment must always be taken into account.

Exposure to quinolone is relevant to delays in diagnosing tuberculosis and the development of drug resistance.

Extending the duration of treatment to 14 days improves eradication rates by >90%.

Tailored therapy to detect fluoroquinolone-resistant strains can be done by culture-based and molecular methods to provide better eradication rates.

Molecular methods are achieved by using a real-time polymerase chain reaction to detect the presence of a gyrA mutation, which is predictive of treatment failure with quinolones-containing triple therapy.